Download PDF
Dtsch Med Wochenschr 2008; 133(39): 1958-1962
DOI: 10.1055/s-0028-1085603
Arzneimittel & Pharmakotherapie | Review article
Neurologie
© Georg Thieme Verlag KG Stuttgart · New York

Olanzapin

OlanzapineK. Wittköpper1 , A. El-Armouche1 , T. Eschenhagen1
  • 1Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
Further Information

Publication History

eingereicht: 1.2.2008

akzeptiert: 14.5.2008

Publication Date:
16 September 2008 (online)

Also available at
    Permissions and Reprints

Einleitung

Olanzapin (Zyprexa®) ist ein zur chemischen Klasse der Thienobenzodiazepin-Derivate gehörender Serotonin-Dopamin-Rezeptorantagonist. Es wurde 1996 in der EU nach Clozapin und Risperidon als drittes atypisches Neuroleptikum zur Behandlung schizophrener Störungen eingeführt. Es ist mit Clozapin, dem Prototyp dieser Arzneimittelgruppe, chemisch eng verwandt.

Literatur

  • 1 Agelink M W, Majewski T, Wurthmann C. et al . Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine.  J Clin Psychopharmacol. 2001;  21 8-13
    Google Scholar
  • 2 Allison D B, Mentore J L, Heo M. et al . Antipsychotic-induced weight gain: a comprehensive research synthesis.  Am J Psychiatry. 1999;  156 1686-96
    Google Scholar
  • 3 Arzneimittelkommission der deutschen Ärzteschaft . Blutbildveränderungen unter dem neueren atypischen Neuroleptikum Olanzapin.  Dtsch Aerztbl. 2001;  3 130
    Google Scholar
  • 4 Arznei-Telegramm. 2000 31: 31-2
    Google Scholar
  • 5 Arznei-Telegramm. 2004 35: 2-4
    Google Scholar
  • 6 Arznei-Telegramm. 2005 36: 51-2
    Google Scholar
  • 7 Beasley Jr C M, Sanger T, Satterlee W. et al . Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial.  Psychopharmacology (Berl). 1996;  124 159-67
    Google Scholar
  • 8 Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial.  Int Clin Psychopharmacol. 1999;  14 339-43
    Google Scholar
  • 9 Bryden K E, Kopala L C. Body mass index increase of 58 % associated with olanzapine.  Am J Psychiatry. 1999;  156 1835-6
    Google Scholar
  • 10 Callaghan J T, Bergstrom R F, Ptak L R. et al . Olanzapine. Pharmacokinetic and pharmacodynamic profile.  Clin Pharmacokinet. 1999;  37 177-93
    Google Scholar
  • 11 Consensus development conference on antipsychotic and obesity and diabetes.  Diabetes Care. 2004;  27 596-601
    Google Scholar
  • 12 Fachinformation. Zyprexa, Olanzapin. Stand 2006
    Google Scholar
  • 13 Henderson D C, Cagliero E, Copeland P M. et al . Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.  Arch Gen Psychiatry. 2005;  62 19-28
    Google Scholar
  • 14 Jayaram M B, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 2006 CD005237
    Google Scholar
  • 15 Kinon B J, Lieberman J A. Mechanisms of action of atypical antipsychotic drugs: a critical analysis.  Psychopharmacology (Berl). 1996;  124 2-34
    Google Scholar
  • 16 Lieberman J A, Stroup T S, McEvoy J P. et al . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.  N Engl J Med. 2005;  353 1209-23
    Google Scholar
  • 17 Lindenmayer J P, Khan A, Iskander A. et al . A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.  J Clin Psychiatry. 2007;  68 368-79
    Google Scholar
  • 18 Rabinowitz J, Lichtenberg P, Kaplan Z. et al . Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.  Am J Psychiatry. 2001;  158 266-9
    Google Scholar
  • 19 Sacchetti E, Valsecchi P, Parrinello G. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.  Schizophr Res. 2008;  98 55-65
    Google Scholar
  • 20 Schwabe U PD. Arzneiverordnungs-Report 2006. Heidelberg; Springer-Verlag 2007
    Google Scholar
  • 21 Stroup T S, McEvoy J P, Swartz M S. et al . The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.  Schizophr Bull. 2003;  29 15-31
    Google Scholar
  • 22 Tandon R. Safety and tolerability: how do newer generation „atypical” antipsychotics compare?.  Psychiatr Q. 2002;  73 297-311
    Google Scholar
  • 23 Tohen M, Greil W, Calabrese J R. et al . Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.  Am J Psychiatry. 2005;  162 1281-90
    Google Scholar
  • 24 Tohen M, Sanger T M, McElroy S L. et al . Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.  Am J Psychiatry. 1999;  156 702-9
    Google Scholar
  • 25 Tollefson G D, Beasley Jr C M, Tamura R N. et al . Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.  Am J Psychiatry. 1997;  154 1248-54
    Google Scholar
  • 26 Tran P V, Dellva M A, Tollefson G D. et al . Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.  Br J Psychiatry. 1998;  172 499-505
    Google Scholar
  • 27 Tran P V, Hamilton S H, Kuntz A J. et al . Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.  J Clin Psychopharmacol. 1997;  17 407-18
    Google Scholar

Katrin Wittköpper

Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg

Martinistraße 52

20246 Hamburg

Phone: 040 42803/2180

Fax: 040 42803/4876

      >